Within the current study, we hypothesized that both D’Amico intermediate- as well as high-risk prostate cancer patients with interval from biopsy to RP ≤3 months compared to those with interval from biopsy to RP >3 and ≤6 months do not differ in BCR rates after RP. This evidence concerns the gene BCR and prostate cancer.